Mark Enyedy - 20 May 2022 Form 4 Insider Report for ImmunoGen, Inc. (IMGN)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
IMGN
Transactions as of
20 May 2022
Transactions value $
$0
Form type
4
Filing time
27 Dec 2022, 16:16:52 UTC
Previous filing
08 Feb 2022
Next filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Award $0 +393,750 $0.000000 393,750 20 May 2022 Common Stock 393,750 $4.55 Direct F1
transaction IMGN Stock Option (Right to Buy) Award $0 +787,500 +200% $0.000000 1,181,250 14 Nov 2022 Common Stock 787,500 $4.55 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
F2 On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.